Collaborations Pharmaceuticals
Collaborations Pharmaceuticals is a Raleigh, North Carolina-based drug discovery company using generative AI to design novel psychoplastogens for substance use disorders. Its lead candidate DM506 is a non-hallucinogenic, non-cardiotoxic synthetic ibogamine derivative (ibogaminalog) that has shown preclinical efficacy in reducing cue-induced heroin-seeking and modulating prefrontal cortex GABA currents in opioid use disorder models.
Development Programmes
1DM506 (Ibogaminalog) — Academic Research, NOT Company Pipeline
IbogaineOpioid use disorder (academic research)
Programme Tracker
Opioid Use Disorder (OUD)
IMPORTANT: DM506 is NOT a Collaborations Pharmaceuticals pipeline asset. It is academic research by Dr Swarup Mitra (Oklahoma State University) and collaborators at Marshall University. Collaborations Pharma focuses on rare/infectious diseases and AI drug discovery.
Milestones
Company milestone
CompletedActual: Jan 1, 2023
PhRMA Foundation Faculty Starter Grant in Drug Discovery awarded to Dr Swarup Mitra (Oklahoma State) for DM506/TBG research in OUD
Why it matters: Grant validates the academic research direction but confirms this is university-based work, not a commercial programme. Collaborations Pharmaceuticals' connection to ibogaine is limited to their MegaSyn AI software demonstrating computational rediscovery of tabernanthalog — not DM506 development.
preclinical-data
CompletedActual: Jun 1, 2024
Key publication: "Novel psychoplastogen DM506 reduces cue-induced heroin-seeking and inhibits tonic GABA currents in the Prelimbic Cortex" — Neurochemistry International (DOI: 10.1016/j.neuint.2024.105785). Academic research from Marshall University, Oklahoma State, University of Kentucky
Why it matters: DM506 (3-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole) is a non-hallucinogenic, non-cardiotoxic, non-tremorgenic ibogalog first described in the 1960s (US Patent 3529062, Novartis). The academic preclinical data shows it reduces heroin-seeking behavior without ibogaine's dangerous side effects. However, this is academic research funded by the PhRMA Foundation, not a commercial drug development programme.
preclinical-data
CompletedActual: Sep 1, 2024
Non-hallucinogenic iboga alkaloid derivatives (including DM506) shown to alleviate neuropathic and visceral pain in mice
Why it matters: Expands DM506's potential indications beyond addiction to chronic pain. Still academic research — no commercial sponsor identified.
Recorded Events
Sep 1, 2024: preclinical-data
Jun 1, 2024: preclinical-data
Jan 1, 2023: Company milestone
Quick Facts
- Type
- Private Biotech
- Lead Stage
- Pre-clinical
- Website
- Visit